Indeed, although antagonists of Drp1 could likely reverse the atrophy observed during cancer-related cachexia [90], a concomitant deletion of Drp1 and Mfn 1 and 2 alleviated symptoms of cardiomyopathy and mice had better survival than when only Drp1- or Mfn 1-2 was deleted [91]. The gene discussed is DNM1L; the disease is cardiomyopathy.